Immunohistochemistry (IHC): 2 – 10 ug/mL, Immunocytochemistry (ICC): 2 – 10 ug/mL, Western Blot (WB): 0.5 – 2 ug/mL
This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF.
50% Glycerol/PBS with 1% BSA and 0.09% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
A peptide corresponding to BRAF V600E mutant
Protein A affinity purified from an animal origin-free culture supernatant
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
B-Raf Proto-Oncogene, Serine/Threonine Kinase , B-Raf1 , B-Raf , Braf1 , Ns7 , Rafb1 , Braf
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008]